Siponimod
Siponimod is a pharmaceutical drug with 9 clinical trials. Currently 5 active trials ongoing. Historical success rate of 66.7%.
Success Metrics
Based on 2 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
1
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
66.7%
2 of 3 finished
33.3%
1 ended early
5
trials recruiting
9
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Determinants of Warfarin Metabolism
Repurposing Siponimod for Alzheimer's Disease
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
Clinical Trials (9)
Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis
Determinants of Warfarin Metabolism
Repurposing Siponimod for Alzheimer's Disease
Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy
Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active Disease
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study
All 9 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 9